Below are the most recent publications written about "Drug Combinations" by people in Profiles.
-
Wise MG, Karlowsky JA, Mohamed N, Kamat S, Sahm DF. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021. Eur J Clin Microbiol Infect Dis. 2023 Sep; 42(9):1135-1143.
-
Karlowsky JA, Hackel MA, Stone GG, Sahm DF. In Vitro Activity of Ceftibuten-Avibactam against ?-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program. Antimicrob Agents Chemother. 2023 01 24; 67(1):e0134622.
-
Kacinko SL, Mohr ALA, Logan BK, Barbieri EJ. Xylazine: Pharmacology Review and Prevalence and Drug Combinations in Forensic Toxicology Casework. J Anal Toxicol. 2022 Oct 14; 46(8):911-917.
-
Bhargava A, Sahoo NK, Das AV, Tyagi M, Kammari P, Sheth J, Kurada J, Shukla S. From Scylla to Charybdis: Fixed drug combinations for tuberculosis and increased ethambutol-induced optic neuropathy in India. Indian J Ophthalmol. 2022 08; 70(8):3073-3076.
-
Karlowsky JA, Lob SH, DeRyke CA, Hilbert DW, Wong MT, Young K, Siddiqui F, Motyl MR, Sahm DF. In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020. Antimicrob Agents Chemother. 2022 05 17; 66(5):e0018922.
-
Karlowsky JA, Kazmierczak KM, Valente MLNF, Luengas EL, Baudrit M, Quintana A, Irani P, Stone GG, Sahm DF. In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019. Braz J Infect Dis. 2021 Nov-Dec; 25(6):101647.
-
Davies MJ, Rosenstock J, Ali A, Russell-Jones D, Souhami E, Palmer K, Ji C, Niemoeller E, Skolnik N. Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin =8%, =64?mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial. Diabetes Obes Metab. 2022 01; 24(1):34-41.
-
Obeid A, Hsu J, Ehmann D, Gao X, Sridhar J, Chiang A, Park CH, Ho AC. TOPICAL DORZOLAMIDE-TIMOLOL WITH INTRAVITREOUS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR RETINAL VEIN OCCLUSION: A PILOT STUDY. Retin Cases Brief Rep. 2021 Mar 01; 15(2):120-126.
-
Skolnik N, Del Prato S, Blonde L, Galstyan G, Rosenstock J. Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes. Adv Ther. 2021 04; 38(4):1715-1731.
-
Eilers SE, Torbeck R, Krishnasamy S, Khorasani H. Safe and Successful Administration of Deoxycholic Acid in a Patient With Chronic Active Liver Disease. Dermatol Surg. 2020 09; 46(9):1240-1242.